& çâÌæÚUæð´ ·¤è ¥ôÚU Îð¹Ùæ ÁæÚUè ÚU¹ð´ ¥ÍæüÌ ¥ÂÙð ÜÿØ ÂÚU ŠØæÙ ÚU¹ð´Ð ãæÚU Ù ×æÙð´, €UØô´ç·¤ ·¤æ× ·¤ÚUÙð âð ¥æÂ·¤ô ©gðàØ ·¤è Âýæç# ãôÌè ãñ ¥õÚU ÁèßÙ ·¤æ ¹æÜèÂÙ ÎêÚU ãôÌæ ãñÐ ÖÜð ãè ÁèßÙ ×ð´ ç·¤ÌÙè Öè ·¤çÆÙæ§ü €UØô´ Ù ¥æ°, çÁ™ææâæ ¥õÚU ©ˆâæã ÕÙæ° ÚU¹ð´Ð ŠØæÙ ÚU¹ð´, ÜÿØ ã×ðàææ ¥æÂ·Ô¤ Âæâ ãôÌð ãñ´ çÁ‹ãð´ ÂæÙð ·Ô¤ çÜ° ÂýØæâ ¥æÂ ·¤Öè Öè àæéM¤ ·¤ÚU â·¤Ìð ãñ´Ð

Almost 20% of breast cancer patients fail to complete prescribed endocrine therapy

Star Health Desk
Around 20% of breast cancer patients do not complete prescribed endocrine therapy, researchers reported at the ESMO Asia 2016 Congress in Singapore. The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
'Adjuvant endocrine treatment such as tamoxifen prevents recurrence and improves absolute survival by 5-10% in patients with oestrogen receptor (ER) positive breast cancer, especially when taken long term (5-10 years)," said lead author Dr Wahyu Wulaningsih, research associate, MRC Unit for Lifelong Health and Ageing at University College London, UK and co-founder of Philippine and Indonesian Scholars (PILAR) Research and Education.
*A substantial proportion of patients who start this treatment do not complete it," continued Wulaningsih. “There is evidence that failure to take the medicine could lead to worse survival. We therefore investigated the reasons for non-adherence so that targeted
strategies could be developed.’
The study included 5,544 women with ER positive breast cancer who collected at least one prescription of aromatase inhibitors or tamoxifen and had five years of follow up data.
Wulaningsih said: "A proportion of breast cancer patients of reproductive age may be concerned about the potential impaa of endocrine treatment on fertility which could explain why they are more likely to stop taking the drugs. Women who wish to have children after a breast cancer diagnosis need more information about their treatment options."
"Research is needed to find out if there are any biological differences in women exposed to HRT before undergoing endocrine treatment for breast cancer," continued Wulaningsih. 'It could be that they are more predisposed to side effeas from endocrine treatment. Personalised approaches may improve adherence in these patients by, for example, tailoring the dosage."
Wulaningsih speculated that unmarried patients might have less social and emotional support to continue taking endocrine therapy.
She said: "Our study identified subgroups of patients who can be targeted with information on the benefits and consequences of endocrine treatment when it is first prescribed and at subsequent visits. Patient support groups could be strengthened, or developed, to help patients overcome the barriers to continuing treatment. Improving adherence should lead to better outcomes for these patients."
Commenting on the findings, Dr Lim Siew Eng, senior consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), said: "Nonadherence to oral endocrine therapy is associated with higher recurrence rates, and is the most important modifiable risk faaor that can affect breast cancer outcomes."
She continued: “In this large study, mainly socioeconomic faaors and not disease nor treatment factors were identified as risks for nonadherence. Pre-diagnostic use of HRT was also identified. These risk faaors could pinpoint certain groups in which striaer compliance monitoring and better management of side effects might improve adherence rates.